Directors and Senior Leadership

Mayne Pharma’s Board and leadership team is comprised of outstanding achievers in the global pharmaceutical industry, finance and business sectors.

Directors

Frank Condella

Frank Condella

Chair

Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent.

Read more
Frank Condella

Frank Condella

Chair

Mr Frank Condella was appointed to the Board on 30 May 2018 and was appointed Chair in September 2021.

Mr Condella, a US resident, has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella’s previous board experience includes Chair of Skyepharma Plc until it merged with Vectura, Vice Chair of Vectura Plc, Independent Director for Fertin Pharma A/S (Denmark), Independent Director for Palladio Biosciences Inc (US), Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chair of the PKD Foundation. Mr Condella holds a Bachelor of Science in Pharmacy and an M.B.A. from Northeastern University, Boston.

Mr Condella is also Chair of the Remuneration and People Committee and the Nomination Committee and a member of the Science and Technology Committee

Shawn Patrick O’Brien

CEO and Managing Director

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products.

Read more

Shawn Patrick O’Brien

CEO and Managing Director

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He was also President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences Inc. and Solstice Neurosciences. Mr O’Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O’Brien began his career at the Upjohn Company of Canada (part of Pfizer).

Mr O’Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.

Mr O’Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.

Patrick J Blake

Patrick J. Blake

Non-Executive Director

Mr Blake, a US resident, has over 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the largest healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation.

Read more
Patrick J Blake

Patrick J. Blake

Non-Executive Director

Mr Patrick Blake was appointed to the Board on 28 June 2018.

Mr Blake, a US resident, has over 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the largest healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Most recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focussed on the US specialty/biotech sector and President of Customer Operations for McKesson Pharmaceutical (US). He is currently an Independent Director of Sutter Health and Deerfield Agency. Mr Blake holds a Bachelor of Arts in Economics from Denison University and an M.B.A. from Pepperdine Graziadio School of Business and Management.

Mr Blake is a member of the Audit & Risk Committee and the Remuneration and People Committee.

Ms Ann Custin

Ann Custin

Non-Executive Director

Ms Ann Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin served as both CFO and Board Director of Siemens Medical Solutions (now Siemens Healthineers), a leading medical technology company with EUR20b in revenues.

Read more
Ms Ann Custin

Ann Custin

Non-Executive Director

Ms Ann Custin was appointed to the Board on 23 March 2022.

Ms Ann Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin served as both CFO and Board Director of Siemens Medical Solutions (now Siemens Healthineers), a leading medical technology company with EUR20b in revenues. Prior to this role, she was Chief Operating and Financial Officer of Scient’x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a director of two women’s health focused companies – ASX-listed Volpara Health and NASDAQ-listed Establishment Labs. She has a Bachelor of Accounting from Queens College and a Certified Public Accountant.

Ms Custin is Chair of the Audit and Risk Committee.

Dr Kathryn MacFarlane

Dr Kathryn MacFarlane

Non-Executive Director

Dr MacFarlane, a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women’s Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at Parke-Davis (now Pfizer).

Read more
Dr Kathryn MacFarlane

Dr Kathryn MacFarlane

Non-Executive Director

Dr Kathryn MacFarlane was appointed to the Board on 1 February 2022.

Dr MacFarlane, a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women’s Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at Parke-Davis (now Pfizer). Dr MacFarlane is a Director of RespireRx Pharmaceuticals, Inc., a member of the Purdue University School of Pharmacy Dean’s Advisory Council and a Founding Member and Advisor to IPhO. She also serves on the Board of Directors for INMED Partnerships for Children, an NGO. She has a Bachelor of Science and Doctor of Pharmacy from Purdue University and completed a Postdoctoral Fellowship with Rutgers University and Hoffmann- LaRoche.

Dr MacFarlane is a member of Mayne Pharma’s Science, Technology and Medical Committee; and the Nomination Committee.

Dr Carolyn Myers

Dr Carolyn Myers

Non-Executive Director

Dr Myers, a US resident, is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen-repelling technology.

Read more
Dr Carolyn Myers

Dr Carolyn Myers

Non-Executive Director

Dr Carolyn Myers was appointed to the Board on 4 October 2021.

Dr Myers, a US resident, is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen-repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. Dr Myers is a Steering Committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals. She has a Ph.D. from the University of British Columbia and an M.B.A. from Rutgers University.

Professor Bruce Robinson

Professor Bruce Robinson

Non-Executive Director

Professor Robinson, a practising Endocrinologist at Sydney’s Royal North Shore Hospital, is Former Dean of University of Sydney’s Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989.

Read more
Professor Bruce Robinson

Professor Bruce Robinson

Non-Executive Director

Professor Bruce Robinson was appointed to the Board on 26 August 2014.

Professor Robinson, a practising Endocrinologist at Sydney’s Royal North Shore Hospital, is Former Dean of University of Sydney’s Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, Professor Robinson has been Chair of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce.

Prof Robinson is Chair of Mayne Pharma’s Science, Technology and Medical Committee and a member of the Nominations Committee.

David Petrie

Non-Executive Director

Mr David Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne.

Read more

David Petrie

Non-Executive Director

Mr David Petrie was appointed to the Board on 1 September 2022.

Mr David Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. Mr Petrie has a Bachelor of Commerce (Honours) and Bachelor of Law (Honours) from the University of Melbourne. He has been a CPA for 30 years and is admitted as Barrister and Solicitor of the Supreme Court of Victoria.

Mr Petrie is a member of Mayne Pharma’s Audit and Risk Committee; and the Remuneration and People Committee.

Leadership

Shawn Patrick O’Brien

CEO and Managing Director

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products.

Read more

Shawn Patrick O’Brien

CEO and Managing Director

Shawn Patrick O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is the founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. Previously, he was the Chairman and CEO of Genomind, a personalised mental health platform company and President and CEO of Cipher Pharmaceuticals, Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He was also President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences Inc. and Solstice Neurosciences. Mr O’Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area. Mr O’Brien began his career at the Upjohn Company of Canada (part of Pfizer).

Mr O’Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress. He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC.

Mr O’Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.

Aaron Gray

Chief Financial Officer

Aaron joined Mayne Pharma in July 2022 and brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20b in revenues and 48,000 employees globally. Most recently, he was Senior Vice President - USA Customer Finance with EUR5b in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens, AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence. He has a Bachelor of Science in Finance and Master of Business Administration (MBA) from the University of Central Florida.

Gerard G. Nahum, M.D.

Gerard G. Nahum, M.D.

Chief Medical Officer

Gerard has more than 30 years of clinical and industry experience. He was previously the Vice President of Global Research & Development, Medicare Devices and eHealth at Bayer Pharmaceuticals. He spent more than 15 years at Bayer including as the Head of Global Clinical Development for Women’s Healthcare as well as for other therapeutic areas including Dermatology and Anti-infectives.

Read more
Gerard G. Nahum, M.D.

Gerard G. Nahum, M.D.

Chief Medical Officer

Gerard has more than 30 years of clinical and industry experience. He was previously the Vice President of Global Research & Development, Medicare Devices and eHealth at Bayer Pharmaceuticals. He spent more than 15 years at Bayer including as the Head of Global Clinical Development for Women’s Healthcare as well as for other therapeutic areas including Dermatology and Anti-infectives. He also spent two years at the US FDA in the Office of New Drugs at the Center for Drug Evaluation and Research. He is a trained physician who is board-certified in Obstetrics and Gynecology, and he previously served as a professor and residency program director at the Duke University School of Medicine before entering the pharmaceutical industry.

Stefan Cross

Stefan Cross

President, International Operations

Stefan joined Mayne Pharma in November 2012 and brings more than 25 years of pharmaceutical industry experience to his role. In 2013, Stefan became President of Mayne Pharma USA, relocating to Raleigh, North Carolina to lead the US business operations. In January 2017, Stefan returned to Australia and is now responsible for all non-US operations and commercial activities.

Read more
Stefan Cross

Stefan Cross

President, International Operations

Stefan joined Mayne Pharma in November 2012 and brings more than 25 years of pharmaceutical industry experience to his role. In 2013, Stefan became President of Mayne Pharma USA, relocating to Raleigh, North Carolina to lead the US business operations. In January 2017, Stefan returned to Australia and is now responsible for all non-US operations and commercial activities. Prior to joining Mayne Pharma, Stefan was Head of Marketing (Asia Pacific) for Hospira Inc. (now part of Pfizer), where he was responsible for expansion of the new product portfolio and on-market product growth across all markets in the region. Prior to joining Hospira, Stefan worked for six years with Mayne Pharma Limited in Europe and Australia and eight years with F H Faulding & Co across strategy, business development/M&A, sales and marketing, HR and finance/IT.

Kimberly Parker

Executive Vice President, General Counsel

Kim joined Mayne Pharma in May 2022 and has more than 20 years of experience covering commercial and IP law, most of which were spent working in the pharmaceutical industry. Prior to joining Mayne Pharma, Kim was Vice President, Business Development Counsel at Alkermes, Inc. Previously, she worked for Novartis for 12 years and at GSK, General Electric and Alston & Bird focusing primarily in the areas of intellectual property, corporate development and patent law. Kim has a BA in Chemistry and BS in Zoology from North Carolina State University. She earned her Juris Doctorate from North Carolina Central University School of Law and is also a registered US Patent Attorney.

Schofield, Brant

Brant Schofield

Executive Vice President, Corporate Development

Brant joined Mayne Pharma in October 2018 and has more than 25 years of experience in the pharmaceutical industry including more than 15 years at Galderma Laboratories, a leading global dermatology and skin health company. Previously, he was Vice President and General Manager Dermatology at Sandoz US where he was responsible for brand and generic product portfolio with revenues of approximately US$500m.

Read more
Schofield, Brant

Brant Schofield

Executive Vice President, Corporate Development

Brant joined Mayne Pharma in October 2018 and has more than 25 years of experience in the pharmaceutical industry including more than 15 years at Galderma Laboratories, a leading global dermatology and skin health company. Previously, he was Vice President and General Manager Dermatology at Sandoz US where he was responsible for brand and generic product portfolio with revenues of approximately US$500m. Prior to Sandoz, he was Vice President of New Business for Nestle Skin Health (parent entity of Galderma) and he was also Vice President of Sales and Marketing for Galderma US, where he led a 300+ person sales and marketing team and was responsible for more than US$1.0b of sales across prescription, over-the-counter and aesthetic dermatology markets.

Donald Pearl

Donald Pearl

Executive Vice President, Specialty Brands

Donald has more than 30 years of pharmaceutical industry experience in sales, operations, marketing and managed care. Prior to joining Mayne Pharma in November 2020, Donald served as Franchise Lead and Vice President of Ipsen’s Neuroscience Division and as Chief Executive Officer for eNeura, a medical device company focused on the treatment of migraines and related ailments.

Read more
Donald Pearl

Donald Pearl

Executive Vice President, Specialty Brands

Donald has more than 30 years of pharmaceutical industry experience in sales, operations, marketing and managed care. Prior to joining Mayne Pharma in November 2020, Donald served as Franchise Lead and Vice President of Ipsen’s Neuroscience Division and as Chief Executive Officer for eNeura, a medical device company focused on the treatment of migraines and related ailments. Earlier, he served in multiple roles at Allergan over more than 20 years, including Vice President of U.S. Neuroscience Sales during the launch of the chronic migraine indication for BOTOX®; Vice President, U.S. Sales Operations, Vice President, Medical Reimbursement and Vice President Internationals Sales & Marketing for SkinMedica an Allergan company. He also co-promoted two migraine products with the British multinational pharmaceutical company GalaxoSmithKline plc while at Allergan. Mr. Pearl has served on the corporate advisory boards for the American Academy of Neurology, Child Neurology Foundation and the American Academy of Physical Medicine and Rehabilitation.

Daniel Moore

Daniel Moore

Executive Vice President, Specialty Products & Patient Solutions

Daniel is responsible for specialty and generic products covering sales and marketing, customer service, pricing and contracts, data and analytical services and channel development. Daniel joined Mayne Pharma in 2015 and has 10 years of healthcare industry experience. Previously, he was Manager for financial planning and analysis at Salix Pharmaceuticals, a specialty pharmaceutical company focused on gastrointestinal disorders.

Hem Pandya

Hem Pandya

Senior Vice President, Head of Generic Product Division

Hem joined Mayne Pharma in October 2021 as Head of the Generic Products Division. He has over 25 years of experience in the generics industry covering commercial, strategic, operational and corporate development roles. Previously he served as an advisor to AmeriSourceBergen’s Global Sourcing Group.

Read more
Hem Pandya

Hem Pandya

Senior Vice President, Head of Generic Product Division

Hem joined Mayne Pharma in October 2021 as Head of the Generic Products Division. He has over 25 years of experience in the generics industry covering commercial, strategic, operational and corporate development roles. Previously he served as an advisor to AmeriSourceBergen’s Global Sourcing Group. He was the co-Founder & Chief Executive Officer of Vensun Pharmaceuticals, a generic specialty pharmaceutical company which was sold to Strides Pharmaceuticals in 2019. Prior to Vensun, he was the the President & Chief Executive Officer of Teligent (IGI) Inc and has held senior executive roles at Andrx Pharmaceuticals (now Teva), Putney, Able Laboratories, Ivax Pharmaceuticals (now Teva), and Faulding/Purepac (now Teva).

Hem currently serves on the Board of Directors of the Association for Accessible Medicines (AAM), SOSRx, LLC (a pharmaceutical platform technology company), Senores Pharmaceuticals (a contract manufacturing and drug development company) and on the Board of Advisors for Anodyne Nanotech, Inc (a microneedle technology company).

Keith Moore

Keith Moore

Vice President, Research and Development

Keith joined Mayne Pharma in 2015 and has more than 20 years of experience in the pharmaceutical industry. Keith has been instrumental in driving Mayne Pharma’s pipeline and the development of branded and generic products. He also worked at Metrics, Inc. for 14 years prior to its acquisition by Mayne Pharma.

Read more
Keith Moore

Keith Moore

Vice President, Research and Development

Keith joined Mayne Pharma in 2015 and has more than 20 years of experience in the pharmaceutical industry. Keith has been instrumental in driving Mayne Pharma’s pipeline and the development of branded and generic products. He also worked at Metrics, Inc. for 14 years prior to its acquisition by Mayne Pharma. Keith has served as Vice President of Analytical Services for Mayne Pharma’s CDMO where he led all laboratory functions including laboratory operations, quality control unit, microbiology, analytical development and method validation, stability, and metrology comprising some 180 employees. Prior to this role, he worked at Salix Pharmaceuticals in technical operations supporting R&D, regulatory, and commercial activities. Keith holds degrees in both Chemistry and Business Administration.

Andrew Herdman

Andrew Herdman

Vice President, Group Human Resources

Andy has more than 25 years of experience across all human resource functions. He has held numerous HR consulting roles and was VP of Human Resources and Strategic Partnerships at Crown American Real Estate Investment Trust. Prior to joining Mayne Pharma, he was Associate Professor, Department of Management at East Carolina University. He has published original research in numerous leading research journals on the impact of progressive human resource practices on firm performance outcomes.

Laura Loftus

Laura Loftus

Associate General Counsel and Company Secretary

Laura was appointed as the Company Secretary on 26 March 2020. Laura has been with Mayne Pharma since May 2014 and is an experienced commercial lawyer with more than ten years of experience. Prior to joining Mayne Pharma, Laura was a solicitor at global law firm DLA Piper. Laura holds a BCom (Accounting) degree and LLB (Hons) degree from Monash University and is a Graduate member of the Australian Institute of Company Directors.

Lisa Pendlebury

Lisa Pendlebury

Vice President, Investor Relations and Communications

Lisa has more than 20 years of experience in the finance industry and has worked with companies including JP Morgan, CVC Asia Pacific and Pacific Brands. Lisa commenced working for Mayne Pharma in 2010 overseeing the investor relations function and was actively involved in all the transformational acquisitions. Lisa has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, investor relations and corporate governance.